PD
MNPR icon

Point72 (DIFC)’s Monopar Therapeutics MNPR Stock Holding History

Point72 (DIFC)’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-196
Closed -$7.13K – 1905
2025
Q1 		$7.13K Buy
+196
New +$7.06K ﹤0.01% 1488

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 (DIFC)'s MNPR Position: Q2 2025 in Review

Point72 (DIFC) sold out of Monopar Therapeutics (MNPR) in Q2 2025, closing a stake of 196 shares — an estimated $7.13K sold.

Point72 (DIFC) first reported a position in MNPR in Q1 2025 and held it in 1 quarter. The position peaked at $7.13K in Q1 2025. 43 funds tracked by Wall St. Rank hold MNPR as of Q2 2025.

  • Point72 (DIFC) reported no remaining Monopar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 196 Monopar Therapeutics shares in Q2 2025, an estimated $7.13K.
  • Point72 (DIFC) first reported a position in Monopar Therapeutics in Q1 2025 and held it in 1 quarter.
  • Point72 (DIFC)'s Monopar Therapeutics position peaked at $7.13K in Q1 2025.
  • 43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.